How Supplied\(^1,2\)

0.5 mL suspension for intramuscular injection, supplied in a single-dose prefilled syringe.

Storage and Handling\(^1,2\)

After shipping, **Prevnar 13\(^\circledast\)** may arrive at temperatures between 2ºC to 25ºC (36ºF to 77ºF). Upon receipt, store refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. Discard if the vaccine has been frozen. Prevnar 13\(^\circledast\) is stable at temperatures up to 25ºC (77ºF) for 4 days. These data are not recommendations for shipping or storage, but may guide decisions for use in case of temporary temperature excursions.

After shipping, **Prevnar 20\(^\text{TM}\)** may arrive at temperatures between 2ºC to 25ºC (36ºF to 77ºF). Upon receipt, store refrigerated at 2ºC to 8ºC (36ºF to 46ºF). Syringes should be stored in the refrigerator horizontally to minimize the resuspension time. Do not freeze. Discard if the vaccine has been frozen. Prevnar 20\(^\text{TM}\) should be administered as soon as possible after being removed from refrigeration. Prevnar 20\(^\text{TM}\) can be administered provided total (cumulative multiple excursions) time out of refrigeration (at temperatures between 8ºC and 25ºC) does not exceed 96 hours. Cumulative multiple excursions between 0ºC and 2ºC are also permitted as long as the total time between 0ºC and 2ºC does not exceed 72 hours. These are not, however, recommendations for storage.

CPT Code\(^3\)

<table>
<thead>
<tr>
<th>Medicare</th>
<th>90670 (Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use)</th>
<th>Medicare</th>
<th>90677 (Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use)</th>
</tr>
</thead>
</table>

CVX Code\(^4\)

| 133      | 216 |

Billing Code for Diagnosis (ICD-10)

<table>
<thead>
<tr>
<th>Medicare</th>
<th>G0009 (Administration of pneumococcal vaccine)(^3)</th>
<th>Medicare</th>
<th>G0009 (Administration of pneumococcal vaccine)(^3)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Commercial</th>
<th>90471 (Immunization administration [includes percutaneous, intradermal, subcutaneous, or intramuscular injections]; 1 vaccine [single or combination vaccine/toxoid])(^3)</th>
<th>Commercial</th>
<th>90471 (Immunization administration [includes percutaneous, intradermal, subcutaneous, or intramuscular injections]; 1 vaccine [single or combination vaccine/toxoid])(^3)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>0005-1971-02</th>
<th>Prefilled Syringe, 1 Dose (10 per package)</th>
<th>0005-2000-10</th>
<th>Prefilled Syringe, 1 Dose (10 per package)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0005-1971-05</td>
<td>Prefilled Syringe, 1 Dose (1 per package)</td>
<td>0005-2000-02</td>
<td>Prefilled Syringe, 1 Dose (1 per package)</td>
</tr>
</tbody>
</table>

NDC Numbers\(^1,2\)


Please see Indications and Important Safety Information on page 2. Please click for Prevnar 20\(^\text{TM}\) and Prevnar 13\(^\circledast\) full Prescribing Information. Prevnar 20\(^\text{TM}\) full Prescribing Information is also available at https://www.prevnar20hcp.com/. Prevnar 13\(^\circledast\) full Prescribing Information is also available at https://www1.pfizerpro.com/product/prevnar-13/adult
Indications

- Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
- In children 6 weeks through 17 years for invasive disease caused by the 13 serotypes, and for children 6 weeks through 5 years of age for otitis media caused by 7 of the 13 serotypes only (4, 6B, 9V, 14, 18C, 19F, and 23F)

Limitations of Use and Effectiveness

- Prevnar 13® will only help protect against *S. pneumoniae* serotypes in the vaccine

Limitations of Use and Effectiveness

- Prevnar 20™ is indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older
- This indication for the prevention of pneumonia caused by *S. pneumoniae* serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA) assay. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial

Important Safety Information

- Severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status, and the potential benefits and risks
- In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
- In children 6 weeks through 17 years, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
- In adults, the most common side effects were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash

Please click for Prevnar 20™ and Prevnar 13® full Prescribing Information. Prevnar 20™ full Prescribing Information is also available at [https://www.prevnar20hcp.com/](https://www.prevnar20hcp.com/). Prevnar 13® full Prescribing Information is also available at [https://www1.pfizerpro.com/product/prevnar-13/adult](https://www1.pfizerpro.com/product/prevnar-13/adult)

References: